On The Watchlist, ImmuPharma (LSE:IMM) CEO Tim McCarthy outlined why the Company’s newly filed patent P140 ‘immunormalizer’, could redefine treatment for autoimmune diseases — and why the market may still be underestimating its potential.

Key Takeaways from the Interview

• Breakthrough science: P140 is positioned as the first “immunormalizer,” a precision platform combining a rapid diagnostic with a therapy designed to restore immune balance instead of broadly suppressing it.
• Broad reach: Initially developed in lupus, P140 could address up to 50 autoimmune indications, potentially placing patients into remission with fewer side effects.
• Large addressable market: Autoimmune diseases represent a ~$100B global therapeutics market, with ~400M patients worldwide, plus a ~$10B diagnostics segment.
• Commercial momentum: Since the patent announcement, ImmuPharma’s share price has rallied. McCarthy believes this is “only the start,” with pharma partners already engaging and deal announcements expected by year-end.
• Solid funding runway: The Company has more than 12 months of cash on hand, bolstered by an ongoing equity facility with Lanstead, warrant exercises and R&D credits Future trials are expected to be financed by partners, reflecting ImmuPharma’s asset-light model.

Investment View

ImmuPharma’s P140 platform offers a differentiated angle in a crowded autoimmune market: it targets immune homeostasis rather than indiscriminately dampening immune responses. If upcoming partnerships confirm clinical and commercial traction, investors could see meaningful upside.

Risks remain — valuation debates, deal timing, and clinical execution — but McCarthy’s confidence in near-term licensing agreements suggests catalysts are on the horizon. For investors looking at innovative biotech plays with broad application potential, ImmuPharma merits close watch.

Disclosure:

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.